Edition:
United Kingdom

Novartis AG (NOVN.S)

NOVN.S on Virt-X Level 1

76.60CHF
2:41pm BST
Change (% chg)

CHF-0.40 (-0.52%)
Prev Close
CHF77.00
Open
CHF76.94
Day's High
CHF77.02
Day's Low
CHF76.32
Volume
2,000,698
Avg. Vol
5,614,585
52-wk High
CHF88.30
52-wk Low
CHF74.22

Latest Key Developments (Source: Significant Developments)

Novartis, Amgen Announce FDA Approval Of Aimovig Treatment For Migraine Prevention
Friday, 18 May 2018 

May 17 (Reuters) - Novartis Ag ::NOVARTIS AND AMGEN ANNOUNCE FDA APPROVAL OF AIMOVIG™ (ERENUMAB-AOOE), A NOVEL TREATMENT DEVELOPED SPECIFICALLY FOR MIGRAINE PREVENTION.EMA MARKETING AUTHORIZATION APPLICATION FOR AIMOVIG IS UNDER REVIEW. NOVARTIS EXPECTS APPROVAL IN EU IN COMING MONTHS.  Full Article

Novartis says set to deliver sales growth, margin expansion through 2022
Wednesday, 16 May 2018 

May 16 (Reuters) - Novartis AG ::SAYS POSITIONED TO DELIVER SALES GROWTH AND MARGIN EXPANSION THROUGH 2022.SAYS ALCON RETURNING TO A POSITION OF STRENGTH AS WORLD'S LEADING EYE CARE DEVICES COMPANY.CEO SAYS FIRM MADE MISTAKES RECENTLY AND WORLD RIGHTLY EXPECTS MORE FROM A LEADING HEALTHCARE COMPANY.SAYS DESPITE CONTINUING US PRICING PRESSURE, GLOBALLY, SANDOZ GROSS MARGIN IS IMPROVING.SAYS IN US, SANDOZ IS OPTIMIZING PORTFOLIO THROUGH TARGETED PRUNING AND LEARNING FROM RECENT SETBACKS.SAYS MANAGEMENT HIGHLIGHTS ACTIONS THAT HAVE RETURNED BUSINESS TO GROWTH AND IMPROVED MARGINS.SAYS ALCON STRATEGIC REVIEW IS ON TRACK WITH ACTION NOT EXPECTED BEFORE FIRST HALF OF 2019.SAYS ALCON EXPECTS TO RETURN TO LONG-TERM, SUSTAINABLE GROWTH WITH MARGINS IN LINE WITH INDUSTRY PEERS.  Full Article

Novartis Successfully Completes Acquisition Of Avexis
Tuesday, 15 May 2018 

May 15 (Reuters) - Novartis AG ::NOVARTIS SUCCESSFULLY COMPLETES ACQUISITION OF AVEXIS, INC..  Full Article

Novartis AG says Cohen contract not linked to CEO dinner with Trump
Wednesday, 9 May 2018 

May 9 (Reuters) - Novartis AG ::SAYS HIRED ESSENTIAL CONSULTANTS BECAUSE BELIEVED MICHAEL COHEN COULD ADVISE ON HOW TRUMP ADMINISTRATION MIGHT APPROACH U.S. HEALTHCARE POLICY, INCLUDING AFFORDABLE CARE ACT.SAYS THE AGREEMENT WAS FOR A TERM OF ONE YEAR, AND PAID ESSENTIAL CONSULTANTS 100,000 USD PER MONTH.SAYS NOVARTIS HAD FIRST MEETING WITH MICHAEL COHEN IN MARCH 2017, SAYS DETERMINED AFTER MEETING THAT COHEN WOULD BE UNABLE TO PROVIDE THE SERVICES ANTICIPATED.SAYS COHEN CONTRACT COULD ONLY BE TERMINATED FOR CAUSE, SO PAYMENTS CONTINUED TO BE MADE UNTIL THE CONTRACT EXPIRED BY ITS OWN TERMS IN FEBRUARY 2018.SAYS CONTRACT WAS IN NO WAY RELATED TO GROUP DINNER CEO NARASIMHAN ATTENDED AT THE WORLD ECONOMIC FORUM IN DAVOS WITH PRESIDENT TRUMP.  Full Article

Novartis Launches Focalview App
Wednesday, 25 Apr 2018 

April 25 (Reuters) - Novartis AG ::NOVARTIS LAUNCHES FOCALVIEW APP, PROVIDING OPPORTUNITY FOR PATIENTS TO PARTICIPATE IN OPHTHALMOLOGY CLINICAL TRIALS FROM HOME.  Full Article

Novartis AG Says Appoints John Tsai Head Of Global Drug Development And Chief Medical Officer
Thursday, 19 Apr 2018 

April 19 (Reuters) - Novartis AG ::SAYS APPOINTS JOHN TSAI HEAD OF GLOBAL DRUG DEVELOPMENT AND CHIEF MEDICAL OFFICER.  Full Article

Novartis Drug Afinitor Disperz Receives FDA Approval To Treat TSC-Associated Partial Onset Seizures
Wednesday, 11 Apr 2018 

April 10 (Reuters) - Novartis AG ::NOVARTIS DRUG AFINITOR DISPERZ® RECEIVES FDA APPROVAL TO TREAT TSC-ASSOCIATED PARTIAL - ONSET SEIZURES.AFINITOR DISPERZ RECEIVES FDA APPROVAL TO TREAT TSC-ASSOCIATED PARTIAL-ONSET SEIZURES.  Full Article

AveXis Says Merger Deal With Novartis Includes That Under Certain Circumstances, Co Will Pay $284 Mln Termination Fee
Monday, 9 Apr 2018 

April 9 (Reuters) - AveXis Inc::AVEXIS - MERGER DEAL WITH NOVARTIS INCLUDES THAT UNDER CERTAIN SPECIFIED CIRCUMSTANCES, CO WILL BE REQUIRED TO PAY $284 MLN TERMINATION FEE TO NOVARTIS.AVEXIS INC - IN CASE OF TERMINATION OF DEAL, NOVARTIS WILL BE REQUIRED TO PAY TO CO A "REVERSE TERMINATION FEE" EQUAL TO $437 MLN - SEC FILING.  Full Article

Oncology Venture Exercises Option To In License Dovitinib A Phase 3 Multi Tyrosine Kinase Inhibitor
Monday, 9 Apr 2018 

April 9 (Reuters) - Oncology Venture Sweden AB ::ONCOLOGY VENTURE EXERCISES OPTION TO IN LICENSE DOVITINIB A PHASE 3 MULTI TYROSINE KINASE INHIBITOR.ENTERED INTO AN AGREEMENT WITH NOVARTIS FOR EXCLUSIVE GLOBAL RIGHTS TO DEVELOP AND COMMERCIALIZE DOVITINIB.NOVARTIS WILL RECEIVE AN UPFRONT PAYMENT, DEVELOPMENT MILESTONES, AND ROYALTIES ON SALES..NOVARTIS WILL BE ISSUED A CONVERTIBLE DEBT-TO-EQUITY NOTE IN A SPINOUT COMPANY THAT OV HAS CREATED.WILL FURTHER REFINE DOVITINIB DRP® BIOMARKER.  Full Article

Novartis AG CEO Says Believes Avexis SMA Medicine Has Multi-Billion Dollar Peak Sales Potential
Monday, 9 Apr 2018 

April 9 (Reuters) - Novartis Ag ::CEO SAYS PLANS TO USE PORTION OF GSK CONSUMER JOINT VENTURE TRANSACTION PROCEEDS TO BUY AVEXIS.CEO SAYS BELIEVES AVEXIS MAIN SMA MEDICINE HAS MULTI-BILLION DOLLAR PEAK SALES POTENTIAL.  Full Article

After hullabaloo, Greek lawmakers drop Novartis probe against ex ministers

ATHENS, May 19 Greece's parliament has no jurisdiction to investigate the role of ten politicians in alleged bribes by Swiss drugmaker Novartis, lawmakers ruled on Saturday, in a controversy which has further polarized a deeply divided political landscape.